Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mecasermin - Teva Pharmaceutical Industries

Drug Profile

Mecasermin - Teva Pharmaceutical Industries

Alternative Names: CEP 120; IGF-1 - Teva Pharmaceutical Industries; Insulin-like growth factor-1 - Teva Pharmaceutical Industries; KW 6151; Myotrophin; Recombinant human insulin-like growth factor-1; Somatomedin-1 - Teva Pharmaceutical Industries

Latest Information Update: 26 Oct 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cephalon
  • Developer Cephalon; Kyowa Hakko; Merck & Co
  • Class Antihyperglycaemics; Growth factors; Peptides
  • Mechanism of Action Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Multiple sclerosis; Peripheral nervous system diseases; Renal failure

Most Recent Events

  • 16 Feb 2016 Biomarkers information updated
  • 18 Sep 2001 Discontinued-III for Amyotrophic lateral sclerosis in Japan (Unknown route)
  • 18 Sep 2001 Suspended - Preregistration for Amyotrophic lateral sclerosis in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top